544738 — Speciality Medicines Income Statement
0.000.00%
- IN₹1.25bn
- IN₹1.31bn
- IN₹752.85m
Annual income statement for Speciality Medicines, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | PROSPECTUS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 404 | 232 | 275 | 583 | 753 |
| Cost of Revenue | |||||
| Gross Profit | 54.1 | 69.6 | 93.2 | 161 | 212 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 383 | 200 | 225 | 494 | 618 |
| Operating Profit | 21.6 | 32.7 | 50.3 | 88.9 | 135 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 21.4 | 29.5 | 45.6 | 86.9 | 130 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 14.8 | 16.9 | 45.5 | 72 | 130 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 14.8 | 16.9 | 45.5 | 72 | 130 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 14.8 | 16.9 | 45.5 | 72 | 130 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 1.68 | 1.92 | 5.17 | 8.19 | 14.9 |